Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 2203-2211 |
| Journal | Annals of surgical oncology |
| Volume | 19 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2012 |
Fingerprint
Keywords
- IR-81258
- METIS-287751
Cite this
}
Prognostic Factors for Locoregional Recurrences in Colon Cancer. / Elferink, M.A.G.; Visser, O.; Wiggers, T.; Otter, R.; Tollenaar, R.A.E.M.; Langendijk, J.A.; Siesling, Sabine.
In: Annals of surgical oncology, Vol. 19, No. 7, 2012, p. 2203-2211.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Prognostic Factors for Locoregional Recurrences in Colon Cancer.
AU - Elferink, M.A.G.
AU - Visser, O.
AU - Wiggers, T.
AU - Otter, R.
AU - Tollenaar, R.A.E.M.
AU - Langendijk, J.A.
AU - Siesling, Sabine
PY - 2012
Y1 - 2012
N2 - Background. There is increased interest in locoregional recurrences of rectal cancer. Despite comparable locoregional recurrence rates in colon cancer, only a few studies on locoregional recurrences among colon cancer patients have been published. This study was designed to identify prognostic factors for locoregional recurrences among patients with colon cancer in the Netherlands. Methods. The study population was composed of patients who underwent radical surgical resections for invasive colon carcinoma, diagnosed in three regions of the Netherlands from 2000 to 2003. The Kaplan-Meier method was used to calculate 5-year locoregional recurrence rates (LRR). Conditional hazard rates were estimated by the lifetable method. Multivariate Cox regression analyses were performed to identify prognostic factors and to calculate a Locoregional Recurrence Risk Score (LRRS). Results. In total 127 of 2,282 patients developed locoregional recurrences within 5 years (LRR 6.4%). The risk of developing a locoregional recurrence was highest at 0.5–1 year after surgery. Patients with left-sided tumors, T3-T4 tumors, and positive lymph nodes and those who did not receive adjuvant chemotherapy were more likely to develop locoregional recurrences. Four risk groups based on the LRRS were defined. Five-year LRR was 2.5% for the very low-risk group and 25.1% for the high-risk group. Conclusions. Although the locoregional recurrence rate in this study was relatively low, it remains a considerable problem. Identifying individual patients who might benefit from adjuvant chemotherapy may reduce the locoregional recurrence rate
AB - Background. There is increased interest in locoregional recurrences of rectal cancer. Despite comparable locoregional recurrence rates in colon cancer, only a few studies on locoregional recurrences among colon cancer patients have been published. This study was designed to identify prognostic factors for locoregional recurrences among patients with colon cancer in the Netherlands. Methods. The study population was composed of patients who underwent radical surgical resections for invasive colon carcinoma, diagnosed in three regions of the Netherlands from 2000 to 2003. The Kaplan-Meier method was used to calculate 5-year locoregional recurrence rates (LRR). Conditional hazard rates were estimated by the lifetable method. Multivariate Cox regression analyses were performed to identify prognostic factors and to calculate a Locoregional Recurrence Risk Score (LRRS). Results. In total 127 of 2,282 patients developed locoregional recurrences within 5 years (LRR 6.4%). The risk of developing a locoregional recurrence was highest at 0.5–1 year after surgery. Patients with left-sided tumors, T3-T4 tumors, and positive lymph nodes and those who did not receive adjuvant chemotherapy were more likely to develop locoregional recurrences. Four risk groups based on the LRRS were defined. Five-year LRR was 2.5% for the very low-risk group and 25.1% for the high-risk group. Conclusions. Although the locoregional recurrence rate in this study was relatively low, it remains a considerable problem. Identifying individual patients who might benefit from adjuvant chemotherapy may reduce the locoregional recurrence rate
KW - IR-81258
KW - METIS-287751
U2 - 10.1245/s10434-011-2183-4
DO - 10.1245/s10434-011-2183-4
M3 - Article
VL - 19
SP - 2203
EP - 2211
JO - Annals of surgical oncology
JF - Annals of surgical oncology
SN - 1068-9265
IS - 7
ER -